Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Ixabepilone in Advanced Renal Cell Carcinoma
NCT00923130Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2009
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival up to 44 months. Started Jan 2009; status: completed.
02
Drugs
ixabepilone
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00923130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923130.